Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Coherus Biosciences Inc’s stock clocked out at $0.97, down -2.38% from its previous closing price of $0.99. In other words, the price has decreased by -$2.38 from its previous closing price. On the day, 0.95 million shares were traded.
Ratios:
To gain a deeper understanding of CHRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Valuation Measures:
As of this moment, Coherus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42.
Stock Price History:
Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 1.07%, while the 200-Day Moving Average is calculated to be -15.96%.
Shares Statistics:
A total of 115.61M shares are outstanding, with a floating share count of 111.29M. Insiders hold about 3.98% of the company’s shares, while institutions hold 53.98% stake in the company.
